vs

Side-by-side financial comparison of AMERISAFE INC (AMSF) and BICYCLE THERAPEUTICS PLC (BCYC). Click either name above to swap in a different company.

AMERISAFE INC is the larger business by last-quarter revenue ($80.1M vs $48.0M, roughly 1.7× BICYCLE THERAPEUTICS PLC). AMERISAFE INC runs the higher net margin — 10.2% vs -42.0%, a 52.2% gap on every dollar of revenue. On growth, BICYCLE THERAPEUTICS PLC posted the faster year-over-year revenue change (1193.3% vs 10.3%). Over the past eight quarters, BICYCLE THERAPEUTICS PLC's revenue compounded faster (56.7% CAGR vs 2.8%).

AMERISAFE Inc. is a specialty insurance provider that focuses exclusively on workers' compensation coverage for small and mid-sized businesses in high-hazard industries including construction, logging, trucking, and manufacturing. It operates across 49 U.S. states, offering tailored insurance policies paired with targeted risk management support for clients.

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical firm developing innovative bicyclic peptide therapies for unmet medical needs. Its core pipeline covers oncology, rare diseases, and immunological disorders, with operations in Europe and North America, and partnerships with global pharma leaders to advance drug candidates to market.

AMSF vs BCYC — Head-to-Head

Bigger by revenue
AMSF
AMSF
1.7× larger
AMSF
$80.1M
$48.0M
BCYC
Growing faster (revenue YoY)
BCYC
BCYC
+1183.0% gap
BCYC
1193.3%
10.3%
AMSF
Higher net margin
AMSF
AMSF
52.2% more per $
AMSF
10.2%
-42.0%
BCYC
Faster 2-yr revenue CAGR
BCYC
BCYC
Annualised
BCYC
56.7%
2.8%
AMSF

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
AMSF
AMSF
BCYC
BCYC
Revenue
$80.1M
$48.0M
Net Profit
$8.1M
$-20.2M
Gross Margin
Operating Margin
-51.5%
Net Margin
10.2%
-42.0%
Revenue YoY
10.3%
1193.3%
Net Profit YoY
-9.0%
61.1%
EPS (diluted)
$0.43
$-0.29

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
AMSF
AMSF
BCYC
BCYC
Q1 26
$80.1M
Q4 25
$81.6M
$48.0M
Q3 25
$82.0M
$11.7M
Q2 25
$81.1M
$2.9M
Q1 25
$72.6M
$10.0M
Q4 24
$74.0M
$3.7M
Q3 24
$78.7M
$2.7M
Q2 24
$75.8M
$9.4M
Net Profit
AMSF
AMSF
BCYC
BCYC
Q1 26
$8.1M
Q4 25
$10.4M
$-20.2M
Q3 25
$13.8M
$-59.1M
Q2 25
$14.0M
$-79.0M
Q1 25
$8.9M
$-60.8M
Q4 24
$13.2M
Q3 24
$14.3M
$-50.8M
Q2 24
$11.0M
$-39.8M
Operating Margin
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
15.6%
-51.5%
Q3 25
21.3%
-558.6%
Q2 25
21.5%
-2965.8%
Q1 25
15.5%
-703.7%
Q4 24
22.7%
Q3 24
22.6%
-2385.9%
Q2 24
18.1%
-498.3%
Net Margin
AMSF
AMSF
BCYC
BCYC
Q1 26
10.2%
Q4 25
12.8%
-42.0%
Q3 25
16.9%
-503.7%
Q2 25
17.2%
-2703.8%
Q1 25
12.3%
-608.9%
Q4 24
17.8%
Q3 24
18.2%
-1898.4%
Q2 24
14.5%
-425.3%
EPS (diluted)
AMSF
AMSF
BCYC
BCYC
Q1 26
$0.43
Q4 25
$0.55
$-0.29
Q3 25
$0.72
$-0.85
Q2 25
$0.73
$-1.14
Q1 25
$0.47
$-0.88
Q4 24
$0.69
Q3 24
$0.75
$-0.74
Q2 24
$0.57
$-0.77

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
AMSF
AMSF
BCYC
BCYC
Cash + ST InvestmentsLiquidity on hand
$34.2M
$628.1M
Total DebtLower is stronger
Stockholders' EquityBook value
$246.6M
$610.0M
Total Assets
$717.6M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
AMSF
AMSF
BCYC
BCYC
Q1 26
$34.2M
Q4 25
$61.9M
$628.1M
Q3 25
$54.7M
$648.3M
Q2 25
$48.5M
$721.5M
Q1 25
$44.8M
$793.0M
Q4 24
$44.1M
$879.5M
Q3 24
$63.7M
$890.9M
Q2 24
$30.6M
$961.4M
Total Debt
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$30.9M
Stockholders' Equity
AMSF
AMSF
BCYC
BCYC
Q1 26
$246.6M
Q4 25
$251.6M
$610.0M
Q3 25
$274.8M
$618.5M
Q2 25
$265.6M
$668.9M
Q1 25
$260.8M
$740.3M
Q4 24
$257.3M
$793.1M
Q3 24
$314.4M
$831.0M
Q2 24
$301.0M
$873.8M
Total Assets
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
$1.1B
$717.6M
Q3 25
$1.2B
$764.0M
Q2 25
$1.2B
$832.2M
Q1 25
$1.2B
$883.9M
Q4 24
$1.2B
$956.9M
Q3 24
$1.3B
$996.7M
Q2 24
$1.2B
$1.1B
Debt / Equity
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
0.04×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
AMSF
AMSF
BCYC
BCYC
Operating Cash FlowLast quarter
$-19.3M
Free Cash FlowOCF − Capex
$-19.9M
FCF MarginFCF / Revenue
-41.5%
Capex IntensityCapex / Revenue
1.2%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-252.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
$11.1M
$-19.3M
Q3 25
$10.7M
$-71.2M
Q2 25
$-8.4M
$-72.8M
Q1 25
$-1.8M
$-86.4M
Q4 24
$24.2M
$-164.7M
Q3 24
$8.4M
$-39.8M
Q2 24
$-2.6M
$-44.6M
Free Cash Flow
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
$8.9M
$-19.9M
Q3 25
$9.8M
$-71.8M
Q2 25
$-9.5M
$-73.3M
Q1 25
$-1.8M
$-87.0M
Q4 24
$23.4M
$-166.0M
Q3 24
$8.4M
$-40.3M
Q2 24
$-2.6M
$-45.0M
FCF Margin
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
10.9%
-41.5%
Q3 25
11.9%
-612.3%
Q2 25
-11.7%
-2509.7%
Q1 25
-2.5%
-871.7%
Q4 24
31.5%
-4475.7%
Q3 24
10.7%
-1504.7%
Q2 24
-3.5%
-481.2%
Capex Intensity
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
2.6%
1.2%
Q3 25
1.1%
5.7%
Q2 25
1.3%
17.1%
Q1 25
0.0%
6.1%
Q4 24
1.1%
33.3%
Q3 24
0.0%
16.3%
Q2 24
0.1%
4.5%
Cash Conversion
AMSF
AMSF
BCYC
BCYC
Q1 26
Q4 25
1.06×
Q3 25
0.77×
Q2 25
-0.61×
Q1 25
-0.20×
Q4 24
1.83×
Q3 24
0.59×
Q2 24
-0.24×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons